Regeneron Pharmaceuticals Inc. (REGN)

Index:

Nasdaq 100

$ 598.16
   
  • Change Today:
    $7.15
  • 52 Week High: $1,201.76
  • 52 Week Low: $490.81
  • Currency: US Dollars
  • Shares Issued: 107.80m
  • Volume: 1,010,305
  • Market Cap: $64,482m
  • RiskGrade: 129

Research into Covid-19 antibody therapy gaining ground - report

By Abigail Townsend

Date: Monday 20 Apr 2020

LONDON (ShareCast) - (Sharecast News) - Antibody therapy for Covid-19 may be available by the autumn, according to a report on biotechnology firms carrying out research.

Antibody drugs are specifically designed to disable a virus, and are being developed to tackle Covid-19 by a range of universities and leading drug companies, including AstraZeneca, Eli Lilly and AbCellera Biologics. Most are looking to start human trials by the end of the summer.

But according to Bloomberg, US biotech Regeneron Pharmaceuticals expects to move faster than its rivals and could have a product ready by autumn.

Regeneron said in March it was looking to develop a novel multi-antibody cocktail that could be used either as a treatment for Covid-19 in or a prophylaxis before exposure. It told investors that it had isolated antibodies from humans who have recovered from Covid-19 as well as other human antibodies from its specially-bred, genetically-modified mice.

It has since narrowed the list of potentially useful antibodies, and last week George Yancopoulos, Regeneron's co-founder and chief scientist, said in an update about a separate Ebola treatment the firm is working on: "Regeneron is now applying the same approach to develop an antibody medicine that can potentially prevent and treat Covid-19, within initial clinical trials expected to begin in June."

In an article published on Monday, Yancopoulos told Bloomberg: "Our technology lets us go in months where it takes others years."

He also told the news agency that Regneron's manufacturing processes were speedier than rivals'. "If they have 10 products, they have 10 plants. We have one process for all our drugs. We've McDonaldlised the manufacturing process." The firm is in the process of retooling one of its US plants to make Covid-19 antibodies, Bloomberg reported.

Most health authorities agree that a vaccine is required to end the Covid-19 pandemic, but it is unlikely one will be developed for another 12 to 18 months. Antibody therapy could be ready sooner, and could be used to ease lockdown restrictions while the search for a vaccine continues.

But there is currently no proof that patients who have recovered from Covid-19 are immune, and there is no guarantee that an antibody therapy would work.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

REGN Market Data

Currency US Dollars
Share Price $ 598.16
Change Today $ 7.15
% Change 1.21 %
52 Week High $1,201.76
52 Week Low $490.81
Volume 1,010,305
Shares Issued 107.80m
Market Cap $64,482m
RiskGrade 129

What The Brokers Say

Strong Buy 9
Buy 11
Neutral 5
Sell 2
Strong Sell 0
Total 27
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Trades for 21-Aug-2025

Time Volume / Share Price
16:00 83,202 @ $598.16
16:00 100 @ $598.45
15:59 157 @ $598.05
15:59 100 @ $598.28
15:59 100 @ $598.08

Top of Page